Author

Heather L. Powell

Observed names: H L Powell, H Powell, H. Powell, Heather Powell

Observed institutions: Brigham and Women's Hospital, Mayo Clinic, Harvard University, Johns Hopkins University, Alberta Hospital Edmonton, University of Alberta Hospital, Johns Hopkins Hospital, Newcastle University

OpenAlex ID: A5080919963

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

2005 · David P. Steensma, Gordon W. Dewald, et al. · Blood · 466

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

2006 · D P Steensma, R F McClure, et al. · Leukemia · 141

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

2005 · Ruben A. Mesa, David Loegering, et al. · Blood · 117

JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia

2006 · Ruben A. Mesa, Heather Powell, et al. · Leukemia Research · 48

Evaluation of CHROMagar Candida for presumptive identification of clinically important Candida species

1998 · Heather L. Powell, Crystal A. Sand, et al. · Diagnostic Microbiology and Infectious Disease · 46

Acquired Isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations

2005 · M Griffiths, J Mason, et al. · Leukemia · 42

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

2006 · R A Mesa, A Tefferi, et al. · Leukemia · 36

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

2006 · Ruben A Mesa, Heather Powell, et al. · PubMed · 20

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

2005 · Ruben A. Mesa, David P. Stensma, et al. · Blood · 3

Evaluation of the In Vitro Activity of the Multikinase Inhibitor BAY 43-9006 (Sorafenib) in Primary Cells from Patients with Myelofibrosis with Myeloid Metaplasia (MMM).

2005 · Joseph W. Smith, Heather Powell, et al. · Blood · 1

Concomitant Myelofibrosis and Plasma Cell Disorders: The Mayo Clinic Experience.

2006 · Ruben A. Mesa, S. Vincent Rajkumar, et al. · Blood

Acquired isodisomy for chromosome 13 is common and associated with FLT3-itd mutations in AML

2005 · M Griffiths, J Mason, et al. · Newcastle University ePrints (Newcastle Univesity)

JAK2 V617F Mutational Status in Myelofibrosis at and before Disease Progression Including Leukemic Transformation: A Longitudinal Study in 68 Patients.

2005 · Ruben A. Mesa, Heather Powell, et al. · Blood

JAK2 (V617F) Mutation Status and Neutrophil Apoptotic Resistance in Myelofibrosis with Myeloid Metaplasia (MMM): Correlation and Potential Identification through Phosphorylation Status of STAT3.

2005 · Ruben A. Mesa, Ayalew Tefferi, et al. · Blood

Incidence and clinical significance of FLT3 internal tandem duplications in acute myeloid leukaemia.

2004 · N Bown, H Powell, et al. · Newcastle University ePrints (Newcastle Univesity)

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

2004 · Ruben A. Mesa, David P. Steensma, et al. · Blood

Ascorbic acid appears to increase the in vitro specificity and sensitivity of arsenic trioxide to the inhibition of primary myeloid colonies from patients with myelofibrosis with myeloid metaplasia

2004 · R. A. Mesa, A. Tefferi, et al. · Journal of Clinical Oncology

Works count: 18

Citation count: 920

H-index: 8

I10-index: 8